Clinical Trial Update: CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CMAB009 in combination with FOLFIRI as first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer; the study status is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• CMAB009
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)

Snippet

Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED